Truist Securities Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $36

Benzinga · 12/01 14:21
Truist Securities analyst Karina Rabayeva initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $36.